Tryptophan-Kynurenine Metabolism and Insulin Resistance in Hepatitis C Patients

Table 1

Kynurenines and insulin resistance in intent-to-treatment HCV patients.

𝑁=60	HOMA2-IR; 1.3 (0.4–3.4)*	HOMA-beta; 153 (57–395)*	KYN; 1030 (480–3100)**	TRP; 13550 (7000–27000)**	KTR; 7.5 (3.2–14.2)*	KYNA; 10 (4.3–36)
HOMA2-IR		𝑟=0.81; 𝑃<0.0001	𝑟=0.32; 𝑃=0.01	𝑟=0.31; 𝑃=0.01	Not significant	Not significant
HOMA-beta	𝑟=0.81; 𝑃<0.0001		𝑟=0.3; 𝑃=0.02	𝑟=0.35; 𝑃=0.01	Not significant	Not significant
KYN	𝑟=0.32; 𝑃=0.01	𝑟=0.30; 𝑃=0.02		𝑟=0.42; 𝑃<0.0003	𝑟=0.62; 𝑃<0.0001	𝑟=0.47; 𝑃=0.0001
TRP	𝑟=0.31; 𝑃=0.01	𝑟=0.35; 𝑃=0.01	𝑟=0.42; 𝑃<0.0003		𝑟=−0.30; 𝑃=0.005	Not significant
KTR	Not significant	Not significant	𝑟=0.62; 𝑃<0.0001	𝑟=−0.30; 𝑃=0.005		Not significant
KYNA	Not significant	Not significant	𝑟=0.47; 𝑃=0.0001	Not significant	Not significant

∗Median (50th percentile) (minimum-maximum).
∗∗pmol/mL (50th percentile) (minimum-maximum).